title: [The concept of biologic progression in metastatic cancer of the prostate hormonally treated].
abstract: A total of 110 patients with hormone-treated metastatic prostate cancer were monitored quarterly with serial PSA determinations. At the first control, 6 patients had progressed clinically, 5 of which had decreased PSA ranging between 9-77%. After a period of response, 69 patients progressed clinically, of which 1 showed no elevation of PSA levels, 14 showed progression concurrent with PSA increase, and 54 showed a period of gradual elevation of PSA over a range of 2-31 months. The probability of biological progression when the first rise occurred ranged between 72-96%, which after a second increase ranged between 92-100%, and all patients with three consecutive increases progressed clinically.
authors.affiliation: Servicio de Urología, Hospital General Universitario Vall d'Hebron, Barcelona.
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.forename: J A
authors.initials: JA
authors.lastname: Lorente
authors.forename: C
authors.initials: C
authors.lastname: Vallejo
authors.forename: G
authors.initials: G
authors.lastname: Encabo
authors.forename: M A
authors.initials: MA
authors.lastname: López-Pacios
authors.forename: J A
authors.initials: JA
authors.lastname: De Torres
authors.forename: A
authors.initials: A
authors.lastname: Soler Roselló
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen